Cognitive Impairments Clinical Trial
Official title:
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder
Currently, no study to date has directly tested a selective D1R agonist in relation to the
cognitive impairment of Schizophrenia without the confound of neuroleptics. The
investigators propose to examine the efficacy of DAR-0100A, a highly selective, full D1R
agonist supported by pre-clinical and preliminary pilot clinical data, in ameliorating the
cognitive deficits in Schizotypal Personality Disordered subjects receiving no medications
including antipsychotics.
The investigators hypothesize that 1) Baseline primary outcome measures will be impaired in
Schizotypal personality disorder (SPD) subjects compared to controls, 2) SPD subjects on
DAR-0100A will show improvement on primary measures greater than healthy controls and SPD
patients randomized to placebo, and 3) SPD patients will show significant improvements on
primary outcome variables on drug compared to placebo.
Working memory deficits are central to the cognitive impairment of schizophrenia and other
psychiatric disorders. The D1 receptor (D1R) is probably the best established mediator of
working memory in neuroscience studies for over three decades and represents a highly
promising therapeutic target for enhancing working memory in these disorders, yet this
mechanism has never been tested in humans. Schizotypal personality disorder (SPD) patients
who evidence moderate, focal impairments in working memory represent a unique population to
test the effect of a D1 agonist on working memory impairment in humans. Cognitive impairment
is the most salient predictor of functional outcome in schizophrenia (SCZ) and is
essentially refractory to conventional treatments. Identifying pharmacologic agents that
target the cognitive deficits of SCZ is thus the top priority in SCZ research, but so far,
clinical trials of a number of drugs with preclinical promise have yielded disappointing
results. Currently, no study to date has directly tested a selective D1R agonist in relation
to the cognitive impairment of SCZ without the confound of neuroleptics. The investigators
propose to examine the efficacy of DAR-0100A, a highly selective, full D1R agonist supported
by pre-clinical and preliminary pilot clinical data, in ameliorating the cognitive deficits
in SPD subjects receiving no medications including antipsychotics. SPD will be classified as
a schizophrenic disorder in DSM-5 and ICD-10. The investigators have characterized the
cognitive deficits of SPD and demonstrated that, as with chronic SCZ, a core component
consists of impairments in working memory. Studies of SPD obviate confounds associated with
SCZ, such as the effects of overt psychotic episodes, medication history, severe, persistent
functional impairment and multiple treatments. Furthermore, the cognitive deficits of SPD
are less global and more readily reversible than those of chronic SCZ, providing a unique
opportunity to test the D1 mechanism of cognitive enhancement. DAR-0100A, which is the
active enantiomer of dihydrexidine (DHX), is a full D1R agonist with a10-60 fold selectivity
over the D2R. DHX administration improves cognition in single doses in young adult and aged
monkeys and rodents. A single treatment with DAR-0100A in adult humans with SCZ was
demonstrated to enhance prefrontal perfusion. Pilot data from our group and Columbia suggest
DAR-0100A improves cognitive performance, particularly working memory, in the schizophrenia
spectrum.
Primary Aims: 1. To perform a 5-year study in which three consecutive days of DAR-0100A at a
dose of 15 mg or placebo are administered intravenously over 30 minutes to 60 patients with
SPD (12/yr) in a between-groups, randomized, double-blind design. Cognitive testing will be
performed at baseline (Day 1) and on the third day of drug/placebo administration (Day 4).
Subjects will return at Day 15 to receive drug (if randomized initially to placebo) or
placebo (if randomized to drug) in a double blind fashion in an identical protocol. This
allows all patients to receive drug for Secondary Aim 1 while maintaining the blind.
Baseline (Day 1) and repeat cognitive testing (Day 4) is also administered to 60 healthy
controls per year (12/yr). The cognitive tests of working memory serving as primary outcome
measures will include the modified AX-CPT (d'), the N-back (% correct at the 2-back
condition), the DOT Task (distance error at 30 second delay - no delay), and the Paced
Auditory Serial Addition Task (PASAT)( correct responses). The investigators will also
include other tests of memory, executive function, and verbal learning for secondary outcome
measures (see Methods) as well as comparison tests not hypothesized to change with drug: the
Benton line orientation test (JLOT) and the Trail Making Test A. 2. To compare changes on
the primary outcome measures from baseline to Day 4 testing between drug and placebo
administration in SPD subjects. 3. To compare primary outcome variables at baseline and
change from baseline to Day 4 testing between patients groups and healthy controls. 4. To
obtain plasma DHX concentrations on Day 4 to evaluate plasma concentrations in relation to
cognitive changes as a potential covariate.
Secondary Aims: 1. To evaluate the change between baseline and Day 4 cognitive testing in
all SPD patients receiving drug in the first or second phase. 2. To evaluate secondary
outcome and comparison variables between SPD patients on placebo and drug.
Primary Hypotheses: 1. Baseline primary outcome measures will be impaired in SPD subjects
compared to controls. 2. SPD subjects on DAR-0100A will show improvement on primary measures
greater than healthy controls and SPD patients randomized to placebo between baseline and
Day 4. 3. SPD patients will show significant improvements on primary outcome variables on
drug compared to placebo but not on comparis¬on perceptual (JLOT) and processing
speed/attentional tasks (Trails A).
It is critical to establish efficacy for cognitive enhancement with a selective D1 agonist
in a schizophrenic disorder with cognitive impairment and without concomitant neuroleptic
treatment to provide momentum for these efforts. The more readily reversible cognitive
impairment of SPD provides a unique opportunity for this critical study of the D1 hypothesis
to pave the way for development for more severe schizophrenic disorders with their
inevitable complicating artifacts.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04470219 -
Digital Support for People With Cognitive Impairment
|
N/A | |
Completed |
NCT01071044 -
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
|
Phase 4 | |
Completed |
NCT02962687 -
Video-Enhanced Care Management for Medically Complex Veterans
|
N/A | |
Completed |
NCT01324024 -
Attention & Memory Impairments in Menopausal Women
|
Phase 4 | |
Recruiting |
NCT05053204 -
Influence Factors and Cognitive Characteristics in Unipolar and Bipolar Depression:Based on the THINC-it Tool
|
||
Recruiting |
NCT02778581 -
Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment
|
N/A | |
Suspended |
NCT00197483 -
Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia
|
Phase 2 | |
Completed |
NCT05585424 -
Effectiveness of a Program Based on Observation-action Training (AOT) in Patients With Cognitive Impairment.
|
N/A | |
Completed |
NCT05822596 -
Tablet-based Interactive Games in Elderly With Cognitive Impairment and Persons With Intellectual Disability
|
N/A | |
Completed |
NCT02830854 -
Molecular Hydrogen for Cognitive Function and Performance in Elderly
|
Phase 3 | |
Withdrawn |
NCT01986777 -
LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy
|
N/A | |
Recruiting |
NCT05896189 -
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
|
N/A | |
Not yet recruiting |
NCT06212726 -
RTL Concussion Communication
|
N/A | |
Completed |
NCT02868684 -
Imaging Biomarkers of Mild Traumatic Brain Injury: a Longitudinal Cohort Study
|
||
Recruiting |
NCT04490330 -
Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients
|
||
Completed |
NCT02677987 -
The "Light for the Brain" Study
|
N/A | |
Completed |
NCT02746484 -
ABILITY - TelerehABILITation: TechnologY-enhanced Multi-domain at Home Continuum of Care Program
|
N/A |